Results 181 to 190 of about 11,335 (243)

Induced-proximity therapeutics for targeted protein and RNA degradation: An organic chemistry Perspective-A review. [PDF]

Curr Res Struct Biol
Rizehbandi M, Dadfar E, Rezaei Nami M, Rezaei Nami M, Rezaei Nami M.   +4 more
europepmc   +1 more source

Targeting Protein Tyrosine Phosphatases via PROteolysis-TArgeting Chimeras (PROTACs): Current Developments and Prospects. [PDF]

Molecules
Maccari R.
europepmc   +1 more source

Antioxidant Natural Compounds Integrated with Targeted Protein Degradation: A Multi-Modal Strategy for Alzheimer's Disease Therapy. [PDF]

Antioxidants (Basel)
Singh DD, Yadav DK, Shin D.
europepmc   +1 more source

PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age. [PDF]

Front Oncol
Cai J, Chen C, Wang J, Zhang X, Cui Y, Zhu Q, Sun H.   +6 more
europepmc   +1 more source

Development of Trivalent PROTACs Based on BRD4-targeting PROTACs

Development of Trivalent PROTACs Based on BRD4-targeting PROTACs
openaire  

Some of the next articles are maybe not open access.

Related searches:

Controlling PROTACs with Light

ChemMedChem, 2020
AbstractProteolysis targeting chimeras, PROTACs, are emerging as a powerful strategy for exerting exogenous control over protein levels, allowing small molecules to exploit the ubiquitin–proteasome pathway for targeted protein degradation. This highlight focuses on the fusion of photochemistry with these bifunctional compounds, which has provided a ...
Shreya Verma, Debasish Manna
openaire   +2 more sources

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.

New England Journal of Medicine
BACKGROUND Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin-proteasome system.
M. Campone, M. De Laurentiis, K. Jhaveri, Xichun Hu, S. Ladoire, A. Patsouris, C. Zamagni, Jiuwei Cui, M. Cazzaniga, T. Çil, K. Jerzak, C. Fuentes, T. Yoshinami, Á. Rodríguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, M. Mouret-Reynier, U. Demirci, YongQiang Zhang, O. Valota, Dongrui R. Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, E. Hamilton   +26 more
semanticscholar   +1 more source

PROTAC-ing tuberculosis

Nature Chemical Biology
Targeted protein degradation has emerged as a promising approach in drug discovery, harnessing a cell's intrinsic machinery to eliminate disease-related proteins. Now, a study paves the way to translating this technology into potential anti-mycobacterial therapies, by exploiting the bacterial protein-degradation complex.
Preti, Delia, Albanese, Valentina, Marconi, Peggy Carla Raffaella   +2 more
openaire   +2 more sources

The aptamer-based RNA-PROTAC

Bioorganic & Medicinal Chemistry, 2023
RNA-binding proteins (RBPs) dysfunction has been implicated in a number of diseases, and RBPs have traditionally been considered to be undruggable targets. Here, targeted degradation of RBPs is achieved based on the aptamer-based RNA-PROTAC, which consists of a genetically encoded RNA scaffold and a synthetic heterobifunctional molecule.
Yan Xu, Yi Yuan, Ding-Qiang Fu, Yi Fu, Shan Zhou, Wan-Ting Yang, Xu-Yang Wang, Guang-Xun Li, Juan Dong, Feng Du, Xin Huang, Qi-Wei Wang, Zhuo Tang   +12 more
openaire   +2 more sources

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation

Pharmaceutics
Proteolysis targeting chimeras (PROTACs), heterobifunctional molecules that hijack the ubiquitin–proteasome system (UPS) to degrade specific proteins, hold great promise in treating diseases driven by traditionally “undruggable” targets.
Endry Wahyu Syahputra, Hyunji Lee, Hyukjun Cho, Hyun Jin Park, Kwang-Su Park, Duhyeong Hwang   +5 more
semanticscholar   +1 more source